New Haven-based Arvinas has hit a biotech trifecta. Over the past month the biotech grabbed recognition as a Fierce 15 company, signed up Genentech as its second marquee collaborator and now has garnered a $41.6 million B round to continue its pipeline development work.

Startup backers Canaan Partners and 5AM Ventures jumped into this new round, getting some help from some crossovers while enrolling RA Capital Management, OrbiMed, and New Leaf Venture Partners into the financial fan club.

Arvinas will use the money to take one giant step beyond protein inhibition and into protein degradation, going after a range of tough targets with a more permanent solution for some serious medical problems.